Intravitreal anti-vascular endothelial growth factor (VEGF) agents usage is widely spread as primary treatment of many vitreoretinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion and other macular edemas [1]. This evidence concerns the gene VEGFA and diabetic macular edema.